Recombinant Human WT1, FLAG-tagged

• Cat.No.: WT1-30863TH
• Product Overview: Recombinant full length human Wilms Tumor Protein with N-terminal Flag-tag expressed in a baculovirus system; amino acids 1-449 ,

Specification

• Description: This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumors. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. In several variants, there is evidence for the use of a non-AUG (CUG) translation initiation site upstream of and in-frame with the first AUG. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated.
• Conjugation: FLAG
• Tissue specificity: Expressed in the kidney and a subset of hematopoietic cells.
• Form: Liquid
• Purity: Immunogen affinity purified
• Storage buffer: Preservative: NoneConstituents: 20% Glycerol, 20mM Tris Cl, 100mM Potassium chloride, 1mM DTT, 0.2mM EDTA, pH 8.0
• Storage: Shipped on dry ice. Upon delivery aliquot and store at -80oC. Avoid freeze / thaw cycles.
• Sequence Similarities: Belongs to the EGR C2H2-type zinc-finger protein family.Contains 4 C2H2-type zinc fingers.

Gene Information

• Gene Name: WT1 Wilms tumor 1 [ Homo sapiens ]
• Official Symbol: WT1
• Synonyms: WT1; Wilms tumor 1; GUD; Wilms tumor protein; AWT1; WAGR; WIT 2
• Gene ID: 7490
• mRNA Refseq: NM_000378
• Protein Refseq: NP_000369
• MIM: 607102
• Uniprot ID: P19544
• Chromosome Location: 11p13
• Pathway: Regulation of Telomerase, organism-specific biosystem; Transcriptional misregulation in cancers, organism-specific biosystem; Transcriptional misregulation in cancers, conserved biosystem
• Function: C2H2 zinc finger domain binding; RNA binding; RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; metal ion binding; protein binding

Citation

WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation

Journal: Molecular cell    PubMed ID: 25601757    Data: 2015/1/15

Authors: Yiping Wang, Mengtao Xiao, Yue Xiong

Article Snippet:The beads were washed three times with the wash buffer (40 mM Tris-HCl/pH7.5, 300 mM NaCl, 0.2% NP-40, 1 mM DTT, 10% Glycerol) and eluted with the Flag peptide (Sigma), then stored at ?80°C.The beads were washed three times with the wash buffer (40 mM Tris-HCl/pH7.5, 300 mM NaCl, 0.2% NP-40, 1 mM DTT, 10% Glycerol) and eluted with the Flag peptide (Sigma), then stored at ?80°C.. For the pull-down assay, 400 ng purified recombinant Flag-WT1 (Creative BioMart) and 200 ng recombinant His-Flag-TET2 CD were mixed with nickel beads (Qiagen) in the wash buffer described above at 4°C overnight.. The beads were collected by centrifugation at 2,000 rpm for 3 min at 4°C and bound proteins were eluted with 300 mM imidazole and subjected to SDS-PAGE.The beads were collected by centrifugation at 2,000 rpm for 3 min at 4°C and bound proteins were eluted with 300 mM imidazole and subjected to SDS-PAGE.

Reviews

10/10/2020

It has been widely employed in protein electron microscopy structure analysis, where it has demonstrated remarkable efficacy.

10/25/2019

Broad applicability make it a valuable asset for a wide range of research endeavors.

05/07/2017

Researchers can rely on the WT1 Protein to deliver reliable and reproducible results, facilitating robust data interpretation and scientific advancements.

Q&As

What therapeutic strategies are being explored for cancers with abnormal WT1 expression?

Targeted therapies and immunotherapies aimed at inhibiting or modulating WT1 expression are being investigated for their potential in cancer treatment.

In what other cancers is the WT1 protein targeted for diagnostic purposes?

Apart from Wilms' tumor, WT1 is examined in leukemia, mesothelioma, and some solid tumors as a diagnostic marker.

Can WT1 be a target for personalized cancer therapy?

Yes, understanding the WT1 status in a patient's cancer can guide the development of personalized treatment plans, potentially improving outcomes.

Are there any ongoing clinical trials focused on the WT1 protein and cancer?

Yes, there are several clinical trials exploring the role of WT1 as a therapeutic target and its potential in cancer treatment.

How does the WT1 protein contribute to the prognosis of cancer patients?

High levels of WT1 expression are often associated with poor prognosis in various cancers, indicating a more aggressive disease course.